Source comparison
BPC-157 vs TB-500: Dosing, Half-Life, and Application Protocols
BPC-157 is a 15-amino-acid peptide derived from a protective gastric protein. It's administered subcutaneously or intramuscularly at doses ranging from 250–500 mcg per day in research protocols. The peptide has no established half-life in human pharmacokinetic
This comparison does not assign a generated winner or score.
- BPC-157 is a 15-amino-acid peptide derived from a protective gastric protein. It's administered subcutaneously or intramuscularly at doses ranging from 250–500 mcg per day in research protocols. The peptide has no established half-life in human pharmacokinetic studies because it lacks FDA approval, but rodent studies suggest a biological activity window of 4–6 hours. Hence the twice-daily dosing schedule in most injury models.
- TB-500 is a 43-amino-acid fragment of Thymosin Beta-4. Research protocols typically use 2–5 mg administered twice weekly via subcutaneous injection. TB-500 has a longer half-life than BPC-157. Approximately 10 days based on equine studies. Which explains the less frequent dosing interval. The peptide circulates systemically and accumulates at injury sites through chemotactic signaling.
- Here's what most peptide guides don't address: peptides for tendon repair are not FDA-approved drugs. They're available through research chemical suppliers operating under the understanding that these compounds are for laboratory investigation, not clinical treatment. Real Peptides manufactures research-grade peptides through small-batch synthesis with third-party purity verification. But purchasing peptides for personal use exists in a regulatory gray zone that requires independent risk assessment.
- Dosing precision matters. BPC-157 at 500 mcg/day shows measurably stronger angiogenic effects than 250 mcg/day in published studies, but higher doses don't produce proportionally greater results. The dose-response curve plateaus beyond 750 mcg/day. TB-500 follows a similar pattern: 5 mg twice weekly outperforms 2 mg twice weekly in tendon healing models, but doses above 10 mg/week show diminishing returns.
- Storage is critical. Both BPC-157 and TB-500 are supplied as lyophilized powder and must be reconstituted with bacteriostatic water before injection. Unreconstituted peptides remain stable at -20°C for 12–24 months. Once reconstituted, BPC-157 should be refrigerated at 2–8°C and used within 30 days. TB-500 remains stable for 60 days under the same conditions. Any temperature excursion above 8°C degrades peptide structure. A vial left on a countertop overnight is no longer viable.